Welcome to our dedicated page for Context Therapeutics SEC filings (Ticker: CNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Context Therapeutics Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors. Form 8-K reports include Regulation FD corporate presentations, operating and financial results, clinical-trial updates, and the FDA Fast Track designation for CTIM-76 in platinum-resistant ovarian cancer.
Proxy and governance filings describe annual meeting matters, director elections, stockholder voting procedures and common stock matters. Charter-related material-event reports document corrections to certificate provisions governing director terms and removal rights, along with associated Delaware court and stockholder-governance disclosures.
Context Therapeutics Inc. is presenting an updated corporate overview focused on T cell engager bispecific antibodies for solid tumors, led by CTIM-76 (CLDN6 x CD3) and CT-202 (Nectin-4 x CD3). Both targets are highly expressed across multiple cancers with sizable relapse/refractory patient populations.
Early Phase 1a data for CTIM-76 in heavily pretreated platinum-resistant ovarian cancer (PROC) show a 29% confirmed overall response rate and 57% disease control rate in RECIST-evaluable patients at target doses, with tumor shrinkage across multiple lesions. Safety data show only Grade 1 cytokine release syndrome in a small number of patients, no Grade ≥2 events, and no dose reductions or discontinuations.
Preclinical and non-human primate studies for CT-202 demonstrate pH-dependent, tumor-selective T cell activation, complete tumor regressions in xenograft models, and high tolerated doses with pharmacokinetics supporting Q2W or Q3W dosing. The company guides to CT-202 first-patient-in during Q3 2026, CTIM-76 Q3W Phase 1a data in Q2 2027, CTIM-76 Phase 1b initiation in Q1 2027, and an expected cash runway into Q4 2027.
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies CTIM-76 and CT-202 for solid tumors. CTIM-76 has FDA Fast Track designation in platinum-resistant ovarian cancer, CT-202 is entering a first-in-human trial, and internal development of CT-95 has been discontinued to focus resources on these programs.
For the six months ended June 30, 2026, the company reported a net loss of $23.2 million, mainly due to higher research and development spending, including a $6.5 million payment under the BioAtla license amendment for CT-202 and increased clinical activity across CTIM-76, CT-95 and CT-202. There was no product revenue.
Cash and cash equivalents were $43.0 million as of June 30, 2026, which management expects will fund operations into the fourth quarter of 2027. The accumulated deficit reached $154.1 million, and the company plans to pursue additional financing, including potential at-the-market equity sales, to support ongoing development and any future commercialization.
Context Therapeutics Inc. reports that on July 29, 2026 it received a written notice from Nasdaq stating its common stock is not in compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Rule, because the closing bid price was below $1.00 per share for 30 consecutive business days.
The company has an initial 180-day grace period, until January 25, 2027, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days, with Nasdaq able to extend that 10-day window. If needed, the company may seek a second 180-day compliance period, subject to meeting other Nasdaq Capital Market listing standards and notifying Nasdaq of its intent to cure the deficiency.
If compliance is not restored within the allowed periods, Nasdaq may move to delist the shares, a decision the company could appeal to a Nasdaq Hearings Panel. Context Therapeutics states it will monitor its bid price and evaluate options, while cautioning there is no assurance it will regain compliance.
Context Therapeutics Inc. has a group of institutional investors reporting a passive ownership position. Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia as control person collectively report beneficial ownership of 3,050,000 shares of Context Therapeutics common stock, representing 3.3% of the class.
All 3,050,000 shares are held by Octagon Investments Master Fund and are subject to shared voting and dispositive power; the reporting persons have no sole voting or dispositive power. The ownership percentage is based on 91,879,177 common shares outstanding as of April 27, 2026, as reported by the issuer. The filing states that the Master Fund holds the shares for the benefit of its investors, with Octagon as investment advisor and Ting Jia as control person.
BlackRock, Inc. reports beneficial ownership of common stock of Context Therapeutics Inc. (CNTX) on Schedule 13G. As of June 30, 2026, BlackRock reports beneficial ownership of 6,169,250 shares of common stock, representing 6.7% of the outstanding class.
BlackRock reports sole voting power over 6,087,367 shares and sole dispositive power over 6,169,250 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares.
Context Therapeutics Inc. director Andy Pasternak received a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $0.576 per share and expire on June 23, 2036. Following this grant, he holds 45,000 options directly.
The option vests and becomes exercisable on the earlier of June 24, 2027, which is the one-year anniversary of the grant date, or the company’s 2027 annual meeting of stockholders, subject to his continued service with the company.
Context Therapeutics Inc. director Stacey Jennifer Evans received a stock option grant covering 45,000 shares of common stock. The option has an exercise price of $0.576 per share and was awarded as a compensation-related grant, not an open-market purchase.
The option vests and becomes exercisable on the earlier of June 24, 2027, or the company’s 2027 annual meeting of stockholders, subject to her continued service with the company. Following this grant, Evans holds stock options for 45,000 shares directly under this award.
Context Therapeutics director Linda West received a new stock option grant as part of her compensation. She was awarded options to acquire 45,000 shares of common stock at an exercise price of $0.576 per share, expiring on June 23, 2036.
The option vests and becomes exercisable on the earlier of June 24, 2027, or the company’s 2027 annual meeting of stockholders, and is subject to her continued service with Context Therapeutics. After this grant, she holds stock options for 45,000 underlying shares directly.
Context Therapeutics Inc. director Karen L. Smith reported receiving a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $0.576 per share and expire on June 23, 2036.
According to the grant terms, the option vests and becomes exercisable on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders, subject to her continued service. Following this award, she holds options to acquire 45,000 shares directly.
Context Therapeutics Inc. director Luke Nathaniel Walker received a grant of 45,000 stock options to buy Common Stock at an exercise price of $0.576 per share. The options vest on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders and expire on June 23, 2036.